Latest news with #AliHedayat
Cision Canada
5 days ago
- Business
- Cision Canada
DRI Healthcare Reports Second Quarter 2025 Results
Subsequent to the end of the quarter, completed the previously announced transaction to internalize its investment management function Portfolio assets generate Total Income of $44.1 million Reactivated NCIB and repurchased ~958 K units for $9.1 million, while redeeming $10 million of Series C Preferred Securities for $9.5 million TORONTO, Aug. 13, 2025 /CNW/ - DRI Healthcare Trust (TSX: (TSX: DHT.U) ("DRI Healthcare") today announced its financial results for the quarter ended June 30, 2025. DRI Healthcare's second quarter 2025 financial statements and Management's Discussion & Analysis ("MD&A") have been filed on SEDAR+ ( All dollar amounts are expressed in U.S. dollars unless otherwise indicated. "Over the past few months, DRI Healthcare has undergone a truly transformational period. By successfully internalizing our external manager, we now have direct alignment between our management team and our unitholders—every decision is focused squarely on creating long-term value.", said Ali Hedayat, DRI Healthcare's Chief Executive Officer. "We've integrated a deeply committed team, sharpened our operating discipline, and are executing with the benefit of a high-quality portfolio of assets with durable growth potential. I'm especially proud that our first pre-approval investment has now been approved, validating our underwriting approach and accelerating future cash flow visibility. Together, these milestones position DRI Healthcare for stronger, more sustainable returns in the years ahead." Q2 Highlights Total Income of $44.1 million; Total Cash Receipts of $40.2 million 1; Adjusted EBITDA of $30.4 million 2; Comprehensive Loss of $0.7 million; Adjusted Cash Earnings per Unit of $0.51 (basic and diluted) 1,2; Received Toronto Stock Exchange ("TSX") approval for normal course issuer bid to allow DRI Healthcare to acquire up to 3,148,536 units of DRI Healthcare ("Units") between May 20, 2025 and May 19, 2026. Repurchased 958,279 Units under its Normal Course Issuer Bid ("NCIB") at an average price of $9.54, totaling $9.1 million under the Automated Purchase Plan ("AUPP"). Paid a quarterly cash distribution of US$0.10 per Unit on July 18, 2025. Subsequent to Quarter End Completed the previously announced transaction to internalize its investment management function, terminated the management agreement with DRI Capital Inc. ("DRI Capital") for a termination payment of $48 million, and acquired the relevant assets of DRI Capital for a purchase price of $1 million. Completed the funding of the Ekterly (sebetralstat) optional payment of $22 million which increases DRI Healthcare's royalty entitlement on net sales up to and including the first $500 million from 5.0% to 6.0% and the potential one-time sales-based milestones payment to KalVista from $50 million to $57 million. Our total investment in Ekterly is now $127 million. Repurchased 208,580 Units under its NCIB at an average price of US$10.24 totaling $2.1 million under the AUPP. Declared a quarterly cash distribution of US$0.10 per Unit for the third quarter of 2025, payable on October 20, 2025 to unitholders of record on September 30, 2025. _________________________ 1 Total Cash Receipts and Adjusted EBITDA are non-GAAP financial measures. Adjusted Cash Earnings per Unit is a non-GAAP ratio. These measures are not standardized measures under IFRS and might not be comparable to similar financial measures disclosed by other issuers. The reconciliation of these measures can be found later in this press release and in DRI Healthcare's MD&A. 2 The weighted average number of basic and diluted units for the purposes of calculating Earnings per Unit for the three months ended June 30, 2025 were 55,685,363 Units. Financial Highlights Three months ended Six months ended (thousands of US dollars, except per Unit amounts) June 30, 2025 June 30, 2024 June 30, 2025 June 30, 2024 Total income 44,130 41,604 88,158 83,671 Management fees 2,657 2,825 6,733 6,989 Performance fees — — 533 231 Amortization of royalty assets 24,751 25,679 49,496 50,725 Impairment of royalty assets — 820 — 5,200 Other expenses 15,375 15,825 31,801 29,800 Gain (loss) on preferred securities (971) 2,176 (971) 2,176 Other loss — (764) — (1,575) Net earnings (loss) 376 (2,133) (1,376) (8,673) Net unrealized gain (loss) on derivative instruments (1,076) 228 (1,156) 1,425 Comprehensive earnings (loss) (700) (1,905) (2,532) (7,248) Net earnings (loss) per Unit – basic 0.01 (0.04) (0.02) (0.15) Net earnings (loss) per Unit – diluted 0.01 (0.04) (0.02) (0.15) Total Cash Receipts 1 40,152 42,955 102,142 106,472 Adjusted EBITDA 1 30,372 32,903 82,031 88,367 Adjusted EBITDA Margin 1 76 % 77 % 80 % 83 % Adjusted Cash Earnings per Unit – Basic 1 0.51 0.49 0.95 0.97 Adjusted Cash Earnings per Unit – Diluted 1 0.51 0.49 0.95 0.97 Weighted average number of Units – Basic 55,685,363 56,426,259 55,743,876 56,392,250 Weighted average number of Units – Diluted 55,685,363 56,426,259 55,743,876 56,392,250 Asset Performance As at June 30, 2025, DRI Healthcare's portfolio included 28 royalty streams on 21 products that address a variety of therapeutic areas, such as oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, lysosomal storage disorders and immunology. On June 30, 2025, the royalty asset portfolio had a book value, net of accumulated amortization, of $774.4 million, which during the three and six months ended June 30, 2025 generated Total Cash Royalty Receipts 1 of $40.2 million and $102.1 million, respectively, and royalty income of $44.8 million and $84.4 million, respectively. On June 30, 2025, the financial royalty asset had a book value of $54.2 million and generated a gain (loss) on the change in its fair value of $(0.9) million and $1.7 million, respectively, during the three and six months ended June 30, 2025. (thousands of US dollars) Cash Receipts Three months ended Six months ended Royalty Asset Therapeutic Area Marketer(s) June 30, 2025 June 30, 2024 June 30, 2025 June 30, 2024 Casgevy Hematology Vertex Pharmaceuticals — — 5,000 — Empaveli/Syfovre Hematology/Ophthalmology Apellis, Sobi 147 2,552 1,272 2,575 Eylea I Ophthalmology Regeneron, Bayer, Santen 1,158 1,321 2,680 2,728 Eylea II Ophthalmology Regeneron, Bayer, Santen 248 285 579 590 Natpara Endocrinology Takeda 222 695 501 1,263 Omidria Ophthalmology Rayner Surgical 8,993 11,261 16,987 19,821 Oracea Dermatology Galderma 1,046 1,886 2,580 4,336 Orserdu I 1 Oncology Menarini 6,410 5,315 14,920 13,335 Orserdu II 1 Oncology Menarini 6,409 3,633 29,329 27,171 Rydapt 2 Oncology Novartis 777 1,953 1,936 4,176 Spinraza Neurology Biogen 3,781 3,272 7,743 7,115 Vonjo I Hematology Sobi 2,553 2,887 5,648 5,789 Vonjo II 1 Hematology Sobi 576 615 1,351 6,220 Xenpozyme Lysosomal Storage Disorder Sanofi 1,913 662 1,913 662 Xolair Immunology Roche, Novartis 2,162 1,666 4,535 4,112 Zejula Oncology GSK 1,103 932 2,052 1,894 Zytiga Oncology Johnson & Johnson 2,230 3,546 2,230 3,546 Other Products 3 Various Various 424 474 886 1,139 Total Cash Royalty Receipts, Cash Receipts and Normalized Cash Receipts 4 40,152 42,955 102,142 106,472 ____________________________ 1 Cash receipts for Orserdu II and Orserdu I for the six months ended June 30, 2025 include $17,593 and $633, respectively, for reclamation of previous royalty deductions. Cash receipts for the six months ended June 30, 2024 include milestone royalty receipts of $2,104 from Orserdu I, $18,939 from Orserdu II and $5,000 from Vonjo II received in Q1 2024. 2 Cash receipts for the six months ended June 30, 2024 includes $1,000 in additional cash receipts related to a one-time payment received in Q1 2024. 3 Other Products includes royalty income from certain other royalty assets as well as royalty assets which are fully amortized and, where applicable, the entitlements to which have generally expired. Comparative figures for royalty assets Simponi, Stelara and Ilaris are included in Other products. 4 Total Cash Receipts, Total Cash Royalty Receipts and Normalized Total Cash Receipts are non-GAAP financial measures. These measures are not standardized measures under IFRS and might not be comparable to similar financial measures disclosed by other issuers. The reconciliation of these measures can be found later in this press release and in the DRI Healthcare's MD&A. Liquidity and Capital On June 30, 2025, DRI Healthcare had cash and cash equivalents of $82.5 million. DRI Healthcare's credit facility had an outstanding principal balance of $344.7 million on June 30, 2025. DRI Healthcare had 55,500,947 Units issued and outstanding on June 30, 2025. Distributions On May 12, 2025, the board of trustees approved a quarterly cash distribution of $0.10 per Unit to unitholders of record as of June 30, 2025, which was paid on July 18, 2025. DRI Healthcare also announced today that its board of trustees has declared a quarterly cash distribution in the amount of $0.10 per Unit for the third quarter of 2025, payable on October 20, 2025, to unitholders of record as of September 30, 2025. Normal Course Issuer Bid During the three months ended June 30, 2025, DRI Healthcare repurchased and cancelled 958,279 Units under its NCIB for an aggregate amount of $9.1 million at a weighted average price of $9.54 per Unit. As previously announced, DRI Healthcare received approval on May 9, 2025 from the TSX to acquire, from time to time, if considered advisable, up to an aggregate of 3,148,536 Units for cancellation. Purchases will conclude on the earlier of the date on which DRI Healthcare has purchased the maximum number of Units permitted under the NCIB and May 19, 2026. In connection with the NCIB, DRI Healthcare established an AUPP where by Units of DRI Healthcare may be repurchased at the discretion of a dealer to the AUPP using commercially reasonable efforts and subject to trading parameters defined in the AUPP. Subsequent to June 30, 2024, DRI Healthcare repurchased an additional 208,580 Units at an average price of US$10.24, totaling $2.1 million under the AUPP. Second Quarter 2025 Conference Call & Webcast As previously announced, management will hold a conference call on Thursday, August 14, 2025 at 8:00 a.m. (ET) to review DRI Healthcare's 2025 second quarter results. You can join the call by dialing 1-888-699-1199 or 416-945-7677 approximately 15 minutes prior to the call to secure a line. A live webcast of the conference call, including a slide presentation, will be available at Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived on DRI Healthcare's website following the call date. Non-GAAP Financial Measures The reconciliations of non-GAAP financial measures and non-GAAP ratios for the three and six months ended June 30, 2025 and 2024 to the most directly comparable measures calculated in accordance with IFRS are presented below. Total Cash Receipts, Normalized Total Cash Receipts and Total Cash Royalty Receipts Total Cash Receipts refers to Total Cash Royalty Receipts plus cash receipts from all products. Total Cash Receipts includes cash receipts from interest as well as non-recurring cash receipts. Total Cash Royalty Receipts refers to aggregate cash royalty receipts and milestone royalty receipts from DRI Healthcare's portfolio of royalty assets and forms part of Total Cash Receipts. Because of the lag between when DRI Healthcare records royalty income and receives the corresponding cash payments on its royalties and milestones, management believes Total Cash Receipts and Total Cash Royalty Receipts are useful measures when evaluating DRI Healthcare's operations, as they represent actual cash generated in respect of all royalty assets held during a period. DRI Healthcare also presents Normalized Total Cash Receipts, which refers to Total Cash Receipts adjusted to remove cash receipts that are not expected to recur in the normal course of operations. Management believes that Normalized Total Cash Receipts will assist readers in evaluating the period-over-period performance of DRI Healthcare's royalty portfolio since Normalized Total Cash Receipts only includes cash receipts generated by royalties and other amounts payable pursuant to the terms of DRI Healthcare's royalty assets. There were no adjustments required to normalize cash receipts for the six months ended June 30, 2025 and 2024. Adjusted EBITDA and Adjusted EBITDA Margin Management believes Adjusted EBITDA provides meaningful information about DRI Healthcare's operating cash flows as it eliminates the effects of other non-cash expenses and accruals and income and expenses that are not expected to recur, that have been recorded on the statement of net earnings (loss) and comprehensive earnings (loss). DRI Healthcare refers to EBITDA when reconciling its net earnings (loss) and comprehensive earnings (loss) to Adjusted EBITDA, but does not use EBITDA as a measure of its performance. Management believes that Adjusted EBITDA Margin is a useful supplemental measure to demonstrate the operating efficiency of DRI Healthcare's business on a cash basis. Three months ended Six months ended (thousands of US dollars) June 30, 2025 June 30, 2024 June 30, 2025 June 30, 2024 Comprehensive earnings (loss) (700) (1,905) (2,532) (7,248) [+] Amortization of intangible royalty assets 24,751 25,679 49,496 50,725 [+] Impairment of intangible royalty assets — 820 — 5,200 [-] Other interest income (356) (577) (654) 17,039 [+] Interest expense 9,028 8,641 18,635 — EBITDA 32,723 32,658 64,945 64,417 [+] Royalties receivable, beginning of period 45,006 45,470 62,362 64,082 [-] Royalties receivable, end of period (49,647) (43,542) (49,647) (43,542) [-] Performance fees payable, beginning of period (2,198) (4,916) (1,665) (5,918) [+] Performance fees payable, end of period — — — — [+] Financial royalty assets, beginning of period 55,088 — 57,527 — [-] Financial royalty assets, end of period (54,184) — (54,184) — [+] Unrealized loss (gain) on marketable securities 115 — (1,420) — [+] Acquired royalties receivable — — — 3,560 [+] Unit-based compensation 970 4,675 1,430 7,242 [+] Board of trustees' unit-based compensation 2 452 198 556 552 [+] Loss (Gain) on preferred securities 971 (2,176) 971 (2,176) [-] Other loss — 764 — 1,575 [-] Net unrealized loss (gain) on derivative instruments 1,076 (228) 1,156 (1,425) Adjusted EBITDA 30,372 32,903 82,031 88,367 [÷] Normalized Total Cash Receipts 40,152 42,955 102,142 106,472 Adjusted EBITDA Margin 76 % 77 % 80 % 83 % _______________________________ 2 Certain members of the board of trustees elected to be compensated fully or partially in Deferred Units ("DUs") under DRI Healthcare's Omnibus Equity Incentive Plan. Adjusted Cash Earnings per Unit Management believes that Adjusted Cash Earnings per Unit provides meaningful information about DRI Healthcare's performance as it provides a measure of the cash generated by DRI Healthcare's assets on a per Unit basis, excluding cash earnings that are not expected to recur. Corporate Update Further to DRI Healthcare's press release of July 1, 2025, subsequent to end of quarter, DRI Healthcare completed its previously announced transaction to internalize its investment management function. As a result of the transaction, the management agreement with DRI Capital was terminated in exchange for a $48 million termination payment and DRI Healthcare internalized the manager function by acquiring the relevant assets of DRI Capital for a purchase price of $1 million. As a result of the transactions contemplated by the asset purchase agreement, the employees of DRI Capital also transitioned to a subsidiary of DRI Healthcare. DRI Healthcare shares that Mr. Amit Kapur, Chief Financial Officer, will be departing DRI Healthcare at the end of September. "Last summer, Amit graciously stepped in at a pivotal moment, helping to steady DRI Healthcare and lay a stronger foundation. He was instrumental in DRI Healthcare's strategic review, playing a significant leadership role in the evaluation of all options and ultimately facilitating the successful internalization of the manager. On behalf of the board of trustees, the team, and our unitholders, we thank Amit for his exceptional skill and leadership during a demanding period and wish him continued success as he brings that same expertise to his next venture." said Gary Collins, Executive Chair of DRI Healthcare. _____________________ 1 Certain members of the board of trustees elected to be compensated fully or partially in DUs under DRI Healthcare's Omnibus Equity Incentive Plan. About DRI Healthcare DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Since our founding in 1989, we have deployed more than $3.0 billion, acquiring more than 75 royalties on 45-plus drugs, including Ekterly, Eylea, Keytruda, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. DRI Healthcare's units are listed and trade on the Toronto Stock Exchange in Canadian dollars under the symbol " and in U.S. dollars under the symbol "DHT.U". To learn more, visit or follow us on LinkedIn. Caution concerning forward-looking statements This news release may contain forward-looking information within the meaning of applicable securities legislation. Forward-looking information can generally be identified by the use of words such as "expect", "continue", "anticipate", "intend", "aim", "plan", "believe", "budget", "estimate", "forecast", "foresee", "close to", "target" or negative versions thereof and similar expressions. Some of the specific forward-looking information in this news release may include, among other things, statements regarding DRI Healthcare's ability to execute on its strategy, the potential and timing of royalty payments, the anticipated royalty income and anticipated sales of the products underlying such royalties, and DRI Healthcare's normal course issuer bid. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond DRI Healthcare's control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These risks and uncertainties include, but are not limited to, the risk that the internalization of DRI Healthcare's manager will not generate the levels of anticipated benefits for DRI Healthcare and its unitholders and those additional risks and uncertainties that are disclosed in DRI Healthcare's most recent annual information form and under "Risk Factors" in DRI Healthcare's Management's Discussion and Analysis. The anticipated royalty terms for products in our portfolio may be shorter than the period of patent protection for the applicable product, depending on many factors, including the entry of generic drugs into the marketplace and competition, all of which are outside our control. No assurance can be given that these are all the factors that could cause actual results to vary materially from the forward-looking statements in this press release. You should not put undue reliance on forward-looking statements. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do occur, the actual results, performance or achievements of DRI Healthcare could differ materially from the results expressed in, or implied by, any forward-looking statements. Certain assumptions underlying the forward-looking information in this news release include: DRI Healthcare's assumptions regarding demand and growth in pharmaceutical sales, R&D and opportunities for royalty investing; the competitive environment in which DRI Healthcare operates; DRI Healthcare's ability to implement its growth strategies; DRI Healthcare's ability to obtain financing and maintain its existing financing on acceptable terms; DRI Healthcare's ability to maintain good business relationships with marketers and other industry partners; timely receipt of cash royalty receipts; expectations regarding the duration of royalties; DRI Healthcare's ability to keep pace with changing consumer preferences; the absence of material adverse changes in DRI Healthcare's industry or the global economy; currency exchange and interest rates; the impact of competition; the changes and trends in DRI Healthcare's industry or the global economy; and stability in laws, rules, regulations and global standards in the pharmaceutical industry. All forward-looking information in this news release speaks as of the date of this news release. DRI Healthcare does not undertake to update any such forward-looking information whether as a result of new information, future events or otherwise except as required by law. Additional information about these assumptions and risks and uncertainties is contained in DRI Healthcare's filings with securities regulators, including its latest annual information form and Management's Discussion and Analysis. These filings are also available at DRI Healthcare's website at
Cision Canada
08-07-2025
- Business
- Cision Canada
DRI Healthcare Comments on FDA Approval and our Increased Investment in KalVista Pharmaceuticals' Ekterly® (sebetralstat)
– Ekterly is the first and only oral on-demand therapy for treating attacks associated with hereditary angioedema – – DRI Healthcare is entitled to a tiered royalty on worldwide net sales of Ekterly – – KalVista has elected to receive additional funding increasing our total investment to $127 million – TORONTO, July 8, 2025 /CNW/ - DRI Healthcare Trust (TSX: (TSX: DHT.U) ("DRI Healthcare") today announced KalVista Pharmaceuticals ("KalVista") has disclosed it has received approval from the U.S. Food and Drug Administration ("FDA") for Ekterly (sebetralstat). Ekterly is approved for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. HAE is a rare genetic disorder characterized by recurring episodes of severe swelling in various parts of the body, including the face, extremities, gastrointestinal tract, and airways. "We are very pleased that the FDA has approved Ekterly as the first and only oral on-demand therapy for treating HAE attacks," said Ali Hedayat, Chief Executive Officer of DRI Healthcare. "The addition of the long-dated Ekterly cash flows demonstrates the value that a pre-approval transaction can bring to our portfolio." "We congratulate our partners at KalVista, who worked diligently to develop Ekterly to help transform the lives of patients who suffer from HAE," added Navin Jacob, Executive Vice President & Chief Investment Officer. KalVista has notified DRI Healthcare that it has elected to receive the optional payment of $22 million as part of the November 2024 royalty transaction. As a result of receiving this one-time payment, the royalty rate on the first sales tranche steps up and the sales-based milestone amount increases. The transaction now entitles DRI Healthcare to a tiered royalty of 6.00% on net sales up to and including $500 million, 1.10% on net sales above $500 million and up to and including $750 million, and 0.25% on net sales above $750 million. KalVista is entitled to a potential one-time sales-based milestone payment of $57 million if annual worldwide net sales of sebetralstat meet or exceed $550 million in any calendar year before January 1, 2031. About DRI Healthcare DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Since our founding in 1989, we have deployed more than $3.0 billion, acquiring more than 75 royalties on 45-plus drugs, including Ekterly, Eylea, Keytruda, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. DRI Healthcare's units are listed and trade on the Toronto Stock Exchange in Canadian dollars under the symbol " and in U.S. dollars under the symbol "DHT.U". To learn more, visit or follow us on LinkedIn.
Cision Canada
01-07-2025
- Business
- Cision Canada
DRI Healthcare Announces Closing of Internalization Transaction
TORONTO, July 1, 2025 /CNW/ - DRI Healthcare Trust (TSX: (TSX: DHT.U) ("DRI Healthcare") today announced that it has completed its previously announced transaction to internalize its investment management function. "We are excited to complete this transaction and begin our next chapter as one integrated organization," said Gary Collins, Executive Chair of DRI Healthcare. "We believe that our new structure will lead to better strategic alignment of interests with unitholders and stronger governance with greater transparency, ultimately benefitting all stakeholders." "We have a strong and dedicated team, now entirely under the DRI Healthcare banner, aligned to invest in high-quality assets and build an industry leading portfolio," said Ali Hedayat, Chief Executive Officer of DRI Healthcare. "With a robust pipeline of strong growth prospects coupled with the newly reduced fee structure, we anticipate enhanced value generation as we continue growing the business over the long term." Transaction Terms As a result of the transaction, the management agreement with DRI Capital Inc. ("DRI Capital") was terminated in exchange for a $48 million termination payment (plus accrued management and performance fees), and the Trust internalized the manager function by acquiring the relevant assets of DRI Capital for a purchase price of $1 million. As a result of the transactions contemplated by the asset purchase agreement, the employees of DRI Capital also transitioned to a Trust subsidiary. DRI Capital also agreed to indemnify the Trust and its affiliates in respect of, among other things, damages relating to the previously disclosed irregularities related to certain alleged consulting and other expenses charged to DRI Healthcare. The transaction was recommended for approval by a special committee of the board composed of independent trustees (the "Special Committee"). In recommending the transaction, the Special Committee evaluated a number of alternatives, including maintaining the status quo, terminating the management agreement for cause, replacing DRI Capital with a new third-party manager, privatizing the Trust, and implementing an internalization transaction. About DRI Healthcare DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Since our founding in 1989, we have deployed more than $3.0 billion, acquiring more than 75 royalties on 45-plus drugs, including Eylea, Keytruda, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. DRI Healthcare's units are listed and trade on the Toronto Stock Exchange in Canadian dollars under the symbol " and in U.S. dollars under the symbol "DHT.U". To learn more, visit or follow us on LinkedIn. Caution concerning forward-looking statements This news release may contain forward-looking information within the meaning of applicable securities legislation. Forward-looking information can generally be identified by the use of words such as "expect", "continue", "anticipate", "intend", "aim", "plan", "believe", "budget", "estimate", "forecast", "foresee", "close to", "target" or negative versions thereof and similar expressions. Some of the specific forward-looking information in this news release may include, among other things, statements regarding the Trust's ability to execute on its strategy, the internalization of the Trust's manager and the terms and conditions, benefits and the value to be provided to unitholders. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Trust's control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These risks and uncertainties include, but are not limited to, the risk that the internalization of the Trust's manager will not generate the levels of anticipated benefits for the Trust and its unitholders, and those additional risks and uncertainties that are disclosed in the Trust's most recent annual information form and under "Risk Factors" in the Trust's Management's Discussion and Analysis. No assurance can be given that these are all the factors that could cause actual results to vary materially from the forward-looking statements in this press release. You should not put undue reliance on forward-looking statements. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do occur, the actual results, performance or achievements of the Trust could differ materially from the results expressed in, or implied by, any forward-looking statements. All forward-looking information in this news release speaks as of the date of this news release. The Trust does not undertake to update any such forward-looking information whether as a result of new information, future events or otherwise except as required by law. Additional information about these assumptions and risks and uncertainties is contained in the Trust's filings with securities regulators, including its latest annual information form and Management's Discussion and Analysis. These filings are also available at the Trust's website at
Yahoo
13-05-2025
- Business
- Yahoo
DRI Healthcare Trust Announces Voting Results of AGM
TORONTO, May 13, 2025 /CNW/ - DRI Healthcare Trust (TSX: (TSX: DHT.U) ("DRI" or "the Trust") is pleased to announce results of voting at its annual general meeting ("AGM") of unitholders held on May 13, 2025. All of the nominees for election as trustees of the Trust referred to in its management information circular dated March 31, 2025 were elected to serve as trustees for the ensuing year, and Deloitte LLP was reappointed as auditors of the Trust. Election of Trustees Voting results for the election of each trustee were as follows: Trustee Votes "for" as a percentage of votes cast for or withheldfor the trustee Votes "withheld" as a percentage of votes cast for or withheld for the trustee Gary Collins 88.19 % 11.81 % Ali Hedayat 90.22 % 9.78 % Kevin Layden 90.13 % 9.87 % Athana Mentzelopoulos 99.75 % 0.25 % Paul Mussenden 88.65 % 11.35 % Poonam Puri 89.58 % 10.42 % Tamara Vrooman 88.26 % 11.74 % Appointment of Auditors Unitholders also voted in favour of reappointing Deloitte LLP as auditors of the Trust and authorizing the board of trustees to fix their remuneration (95.75% in favour). About DRI Healthcare Trust The Trust is managed by DRI Capital Inc., a pioneer in global pharmaceutical royalty monetization. Since its initial public offering in 2021, the Trust has deployed more than $1.0 billion, acquiring more than 25 royalties on 20-plus drugs, including Eylea, Orserdu, Omidria, Spinraza, Stelara, Vonjo, Zejula and Zytiga. The Trust's units are listed and trade on the Toronto Stock Exchange in Canadian dollars under the symbol " and in U.S. dollars under the symbol "DHT.U". To learn more, visit or follow us on LinkedIn. SOURCE DRI Healthcare Trust View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
